What one share of Zhengye Biotechnology Holding Limited holds
Our mission is to become a world-leading manufacturer of veterinary vaccines and to provide reliable veterinary vaccines to the world.
Zhengye Biotechnology Holding Limited’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.34 |
|---|---|
| Profit | −$0.21 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | $0.04 |
| Cash and investments | $0.15 |
| Debt | $0.23 |
| Book value | $0.75 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $0.85 | $0.15 | $0.09 | −$0.03 | — | $1.13 |
| 2023 | $0.66 | $0.10 | $0.02 | $0.13 | — | $0.84 |
| 2024 | $0.57 | $0.03 | $0.04 | $0.08 | — | $0.85 |
| 2025 | $0.34 | −$0.21 | $0.00 | $0.04 | — | $0.75 |
Common questions about Zhengye Biotechnology Holding Limited
How much does one share of Zhengye Biotechnology Holding Limited earn?
Over its latest fiscal year, Zhengye Biotechnology Holding Limited lost $0.21 for each share on $0.34 of sales.
Does Zhengye Biotechnology Holding Limited pay a dividend?
Zhengye Biotechnology Holding Limited didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Zhengye Biotechnology Holding Limited’s book value per share?
Zhengye Biotechnology Holding Limited’s book value is $0.75 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of December 31, 2025.
How much cash and debt does each share of Zhengye Biotechnology Holding Limited have?
Each share of Zhengye Biotechnology Holding Limited has $0.15 of cash and investments and $0.23 of debt, as of December 31, 2025.
What is Zhengye Biotechnology Holding Limited’s free cash flow per share?
$0.04 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has Zhengye Biotechnology Holding Limited bought back shares?
Zhengye Biotechnology Holding Limited’s share count rose about 4% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.